vorapaxar and Ureteral-Obstruction

vorapaxar has been researched along with Ureteral-Obstruction* in 1 studies

Other Studies

1 other study(ies) available for vorapaxar and Ureteral-Obstruction

Article	Year
The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. Clinical science (London, England : 1979), 2020, 11-13, Volume: 134, Issue:21 Protease-activated receptor (PAR)-1 has emerged as a key profibrotic player in various organs including kidney. PAR-1 activation leads to deposition of extracellular matrix (ECM) proteins in the tubulointerstitium and induction of epithelial-mesenchymal transition (EMT) during renal fibrosis. We tested the anti-fibrotic potential of vorapaxar, a clinically approved PAR-1 antagonist for cardiovascular protection, in an experimental kidney fibrosis model of unilateral ureteral obstruction (UUO) and an AKI-to-chronic kidney disease (CKD) transition model of unilateral ischemia-reperfusion injury (UIRI), and dissected the underlying renoprotective mechanisms using rat tubular epithelial cells. PAR-1 is activated mostly in the renal tubules in both the UUO and UIRI models of renal fibrosis. Vorapaxar significantly reduced kidney injury and ameliorated morphologic changes in both models. Amelioration of kidney fibrosis was evident from down-regulation of fibronectin (Fn), collagen and α-smooth muscle actin (αSMA) in the injured kidney. Mechanistically, inhibition of PAR-1 inhibited MAPK ERK1/2 and transforming growth factor-β (TGF-β)-mediated Smad signaling, and suppressed oxidative stress, overexpression of pro-inflammatory cytokines and macrophage infiltration into the kidney. These beneficial effects were recapitulated in cultured tubular epithelial cells in which vorapaxar ameliorated thrombin- and hypoxia-induced TGF-β expression and ECM accumulation. In addition, vorapaxar mitigated capillary loss and the expression of adhesion molecules on the vascular endothelium during AKI-to-CKD transition. The PAR-1 antagonist vorapaxar protects against kidney fibrosis during UUO and UIRI. Its efficacy in human CKD in addition to CV protection warrants further investigation. Topics: Animals; Biomarkers; Cell Hypoxia; Endothelial Cells; Epithelial Cells; Epithelial-Mesenchymal Transition; Extracellular Matrix Proteins; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Inflammation; Kidney; Kidney Tubules; Lactones; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Oxidative Stress; Pyridines; Rats; Reactive Oxygen Species; Receptor, PAR-1; Reperfusion Injury; Smad3 Protein; Thrombin; Transforming Growth Factor beta; Up-Regulation; Ureteral Obstruction	2020

Article

Year

The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis.

Clinical science (London, England : 1979), 2020, 11-13, Volume: 134, Issue:21

Protease-activated receptor (PAR)-1 has emerged as a key profibrotic player in various organs including kidney. PAR-1 activation leads to deposition of extracellular matrix (ECM) proteins in the tubulointerstitium and induction of epithelial-mesenchymal transition (EMT) during renal fibrosis. We tested the anti-fibrotic potential of vorapaxar, a clinically approved PAR-1 antagonist for cardiovascular protection, in an experimental kidney fibrosis model of unilateral ureteral obstruction (UUO) and an AKI-to-chronic kidney disease (CKD) transition model of unilateral ischemia-reperfusion injury (UIRI), and dissected the underlying renoprotective mechanisms using rat tubular epithelial cells. PAR-1 is activated mostly in the renal tubules in both the UUO and UIRI models of renal fibrosis. Vorapaxar significantly reduced kidney injury and ameliorated morphologic changes in both models. Amelioration of kidney fibrosis was evident from down-regulation of fibronectin (Fn), collagen and α-smooth muscle actin (αSMA) in the injured kidney. Mechanistically, inhibition of PAR-1 inhibited MAPK ERK1/2 and transforming growth factor-β (TGF-β)-mediated Smad signaling, and suppressed oxidative stress, overexpression of pro-inflammatory cytokines and macrophage infiltration into the kidney. These beneficial effects were recapitulated in cultured tubular epithelial cells in which vorapaxar ameliorated thrombin- and hypoxia-induced TGF-β expression and ECM accumulation. In addition, vorapaxar mitigated capillary loss and the expression of adhesion molecules on the vascular endothelium during AKI-to-CKD transition. The PAR-1 antagonist vorapaxar protects against kidney fibrosis during UUO and UIRI. Its efficacy in human CKD in addition to CV protection warrants further investigation.

Topics: Animals; Biomarkers; Cell Hypoxia; Endothelial Cells; Epithelial Cells; Epithelial-Mesenchymal Transition; Extracellular Matrix Proteins; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Inflammation; Kidney; Kidney Tubules; Lactones; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Oxidative Stress; Pyridines; Rats; Reactive Oxygen Species; Receptor, PAR-1; Reperfusion Injury; Smad3 Protein; Thrombin; Transforming Growth Factor beta; Up-Regulation; Ureteral Obstruction

2020